| Variables: Mean (SD) |
Groups |
|
Comparisonb) |
| Supplementation (n=7) |
Placebo (n=6) |
Comparisona) |
ARA |
Placebo |
| Baseline |
8 week |
16 week |
Baseline |
8 week |
16 week |
F |
P |
U |
P |
U |
P |
| DHA |
4.13
(1.50) |
4.08
(0.99) |
4.11 (1.20) |
3.33 (1.15) |
3.01
(0.62) |
2.96
(0.77) |
0.01 |
0.92 |
23.00 |
0.90 |
15.00 |
0.70 |
| EPA |
1.62 (1.24) |
1.57 (0.89) |
1.53 (1.01) |
1.64 (0.74) |
1.30 (0.52) |
1.03 (0.20) |
0.18 |
0.69 |
23.50 |
0.90 |
6.00 |
0.07 |
| ARA |
5.16 (0.77) |
6.15 (0.77) |
6.36 (0.94) |
6.25 (0.95) |
5.24 (0.69) |
5.34 (0.52) |
0.00 |
0.99 |
7.0 |
0.03* |
9.00 |
0.18 |
| ARA/DHA |
1.36 (0.40) |
1.57 (0.33) |
1.61 (0.32) |
2.02 (0.62) |
1.71 (0.26) |
1.66
(0.45) |
0.02 |
0.90 |
16.0 |
0.32 |
10.00 |
0.24 |
|
Treatment group received supplementation with arachidonic acid (ARA) and docosahexaenoic acid (DHA) for 16 weeks in the course of double-blind placebo-controlled trial. ARA, arachidonic acid; DHA, docosahexaenoic acid; EPA, Eicosapentaenoic acid.
a) Mann-Whitney U-test at the 16 weeks compared to changes from the baseline, *p<0.05.
b) Mann-Whitney U-test at the 16 weeks, *p<0.05. |
| Table 3: Plasma levels of EPA, DHA, ARA and ARA/DHA ratio in a 16-week double-blind placebo-controlled trial. |
